This page shows prior authorization criteria extracted from Cigna (eviCore)'s published imaging guidelines. 62 matching coverage rules found for this procedure.
Abdominal Pain
Indication Code: AB-2.2
Abdominal Wall Mass
Indication Code: AB-13.1
Abnormal Uterine Bleeding (AUB)
Indication Code: PV-2.1
Adenomyosis
Indication Code: PV-4.1
Amenorrhea
Indication Code: PEDPV-4.1
Blunt Abdominal Trauma
Indication Code: AB-10.1
Complex Adnexal Masses
Indication Code: PV-5.3
Costello Syndrome
Indication Code: PEDONC-2.14
Endometrial Polyp
Indication Code: PV-12.2
Endometriosis
Indication Code: PV-6.1
Familial Adenomatous Polyposis (FAP) and Related Conditions
Indication Code: PEDONC-2.7
General Guidelines
Indication Code: PV-1.0
General Guidelines
Indication Code: PEDPV-1.0
General Guidelines – Overview
Indication Code: PV-1.1
Hematuria
Indication Code: PEDAB-7
Hematuria
Indication Code: PEDAB-7
Hysteroscopically Placed Tubal Occlusion Device
Indication Code: PV-10.2
Indeterminate Intra-Abdominal Mass
Indication Code: AB-13.2
Inguinal or Femoral Hernia, or Indeterminate Groin Pain
Indication Code: AB-12.1
Initial Infertility Evaluation, Female
Indication Code: PV-9.1
Intrauterine Device
Indication Code: PV-10.1
Left Lower Quadrant Pain
Indication Code: PEDAB-29
Left Lower Quadrant Pain
Indication Code: PEDAB-29
Leiomyoma/Uterine Fibroids
Indication Code: PV-12.1
Li-Fraumeni Syndrome (LFS)
Indication Code: PEDONC-2.2
LUMBAR Syndrome
Indication Code: PEDPVD-5.4
Male Pelvic Disorders
Indication Code: PV-19.1
Melanoma – Surveillance/Follow-up
Indication Code: ONC-5.4
Other Renal Cell Cancer Predisposition Syndromes
Indication Code: PEDONC-2.17
Ovarian Cancer – Suspected/Diagnosis
Indication Code: ONC-21.2
Patent Urachus
Indication Code: PV-23.1
Patent Urachus
Indication Code: PEDPV-15.1
Pediatric Aggressive Mature B-Cell Non-Hodgkin Lymphomas (NHL)
Indication Code: PEDONC-5.3
Pelvic Inflammatory Disease
Indication Code: PV-7.1
Pelvic Pain/Dyspareunia, and Ovarian Torsion
Indication Code: PEDPV-7.1
Pelvic Pain/Dyspareunia, Female
Indication Code: PV-11.1
Pelvic Prolapse
Indication Code: PV-22.3
Penis-Soft Tissue Mass
Indication Code: PV-18.1
Periurethral cysts, Skene duct cyst, Bartholin's gland cysts and Gartner’s duct cyst
Indication Code: PV-13.1
Polycystic Ovary Syndrome
Indication Code: PEDPV-8.1
Polycystic Ovary Syndrome (PCOS)
Indication Code: PV-8.1
Post-Transplant Imaging
Indication Code: PEDONC-20.2
Primary Amenorrhea
Indication Code: PV-3.2
Retained Products of Conception
Indication Code: PV-2.2
Rhabdoid Tumor Predisposition Syndrome
Indication Code: PEDONC-2.11
Screening for Ovarian Cancer
Indication Code: ONC-21.1
Secondary Amenorrhea
Indication Code: PV-3.1
Simple Cysts
Indication Code: PV-5.2
Splenic Trauma
Indication Code: AB-34.2
Suspected Adnexal Mass – Initial Evaluation
Indication Code: PV-5.1
Suspected Physical Child Abuse
Indication Code: PEDMS-7
Suspected Uterine Mass
Indication Code: PV-12.0
Testicular, Ovarian and Extragonadal Germ Cell Tumors – Initial Work-Up/Staging
Indication Code: ONC-20.1
Testicular, Ovarian and Extragonadal Germ Cell Tumors – Restaging/Recurrence
Indication Code: ONC-20.2
Testicular, Ovarian and Extragonadal Germ Cell Tumors – Surveillance
Indication Code: ONC-20.3
Ureteral and/or Bladder Trauma or Injury
Indication Code: PV-25.1
Urethral Diverticula
Indication Code: PV-13.2
Uterine Anomalies
Indication Code: PV-14.1
Uterine Cancer – Initial Work-Up/Staging
Indication Code: ONC-22.2
Uterine Cancer – Suspected/Diagnosis
Indication Code: ONC-22.1
Vaginal Anomalies
Indication Code: PV-14.2
Vaginal Masses
Indication Code: PV-13.3
Standard prior authorization requests are typically processed within 3–5 business days. Urgent/expedited requests may be processed within 24–72 hours when clinically necessary.
Most plans allow 30–60 days to file a first-level appeal. Expedited appeals for urgent cases are typically processed within 72 hours.